-
1
-
-
0023120595
-
Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma
-
Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987 28 : 288 92.
-
(1987)
J Nucl Med
, vol.28
, pp. 288-92
-
-
Paul, R.1
-
2
-
-
0032548107
-
A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease
-
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998 339 : 1506 14.
-
(1998)
N Engl J Med
, vol.339
, pp. 1506-14
-
-
Hasenclever, D.1
Diehl, V.2
-
3
-
-
4444326818
-
Follicular lymphoma international prognostic index
-
Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004 104 : 1258 65.
-
(2004)
Blood
, vol.104
, pp. 1258-65
-
-
Solal-Celigny, P.1
Roy, P.2
Colombat, P.3
-
4
-
-
0027444652
-
A predictive model for aggressive non-Hodgkin's lymphoma
-
The International Non-Hodgkin's Lymphoma Prognostic Factors Project.
-
The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993 329 : 987 94.
-
(1993)
N Engl J Med
, vol.329
, pp. 987-94
-
-
-
5
-
-
0030430098
-
Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: A prospective pilot study
-
Bendini M, Zuiani C, Bazzocchi M, Dalpiaz G, Zaja F, Englaro E. Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study. MAGMA 1996 4 : 213 24.
-
(1996)
MAGMA
, vol.4
, pp. 213-24
-
-
Bendini, M.1
Zuiani, C.2
Bazzocchi, M.3
Dalpiaz, G.4
Zaja, F.5
Englaro, E.6
-
6
-
-
0031790988
-
Comparison of MR imaging and CT in discriminating tumor infiltration of bone and bone marrow in the skull base
-
Tomura N, Hirano H, Sashi R, Hashimoto M, Kato K, Takahashi S, Watanabe O, Watarai J. Comparison of MR imaging and CT in discriminating tumor infiltration of bone and bone marrow in the skull base. Comput Med Imaging Graph 1998 22 : 41 51.
-
(1998)
Comput Med Imaging Graph
, vol.22
, pp. 41-51
-
-
Tomura, N.1
Hirano, H.2
Sashi, R.3
Hashimoto, M.4
Kato, K.5
Takahashi, S.6
Watanabe, O.7
Watarai, J.8
-
7
-
-
0031610568
-
Cross-sectional imaging with CT and/or MRI of pediatric chest tumors
-
Wyttenbach R, Vock P, Tschappeler H. Cross-sectional imaging with CT and/or MRI of pediatric chest tumors. Eur Radiol 1998 8 : 1040 6.
-
(1998)
Eur Radiol
, vol.8
, pp. 1040-6
-
-
Wyttenbach, R.1
Vock, P.2
Tschappeler, H.3
-
8
-
-
0030091284
-
Present state and future role of gallium-67 scintigraphy in lymphoma
-
Front D, Israel O. Present state and future role of gallium-67 scintigraphy in lymphoma. J Nucl Med 1996 37 : 530 2.
-
(1996)
J Nucl Med
, vol.37
, pp. 530-2
-
-
Front, D.1
Israel, O.2
-
9
-
-
0037083501
-
Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma
-
Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002 94 : 879 88.
-
(2002)
Cancer
, vol.94
, pp. 879-88
-
-
Kostakoglu, L.1
Leonard, J.P.2
Kuji, I.3
Coleman, M.4
Vallabhajosula, S.5
Goldsmith, S.J.6
-
10
-
-
0036124658
-
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma
-
Wirth A, Seymour JF, Hicks RJ, Ware R, Fisher R, Prince M, MacManus MP, Ryan G, Januszewicz H, Wolf M. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002 112 : 262 8.
-
(2002)
Am J Med
, vol.112
, pp. 262-8
-
-
Wirth, A.1
Seymour, J.F.2
Hicks, R.J.3
Ware, R.4
Fisher, R.5
Prince, M.6
MacManus, M.P.7
Ryan, G.8
Januszewicz, H.9
Wolf, M.10
-
11
-
-
0038467319
-
Gallium-67 scintigraphy: A cornerstone in functional imaging of lymphoma
-
Even-Sapir E, Israel O. Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma. Eur J Nucl Med Mol Imaging 2003 30 (Suppl. 1 S65 81.
-
(2003)
Eur J Nucl Med Mol Imaging
, vol.30
, Issue.1
-
-
Even-Sapir, E.1
Israel, O.2
-
12
-
-
0842344572
-
FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: A blinded comparison
-
Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, Mauch PM, Canellos GP, van den Abbeele AD. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma 2004 45 : 85 92.
-
(2004)
Leuk Lymphoma
, vol.45
, pp. 85-92
-
-
Friedberg, J.W.1
Fischman, A.2
Neuberg, D.3
Kim, H.4
Takvorian, T.5
Ng, A.K.6
Mauch, P.M.7
Canellos, G.P.8
Van Den Abbeele, A.D.9
-
13
-
-
0036854527
-
18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients
-
Van Den Bossche B., Lambert B, De Winter F, Kolindou A, Dierckx RA, Noens L, Van De Wiele C. 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients. Nucl Med Commun 2002 23 : 1079 83.
-
(2002)
Nucl Med Commun
, vol.23
, pp. 1079-83
-
-
Van Den Bossche, B.1
Lambert, B.2
De Winter, F.3
Kolindou, A.4
Dierckx, R.A.5
Noens, L.6
Van De Wiele, C.7
-
14
-
-
6944255075
-
18F-FDG PET is superior to 67Ga SPECT in the staging of non-Hodgkin's lymphoma
-
Yamamoto F, Tsukamoto E, Nakada K, Takei T, Zhao S, Asaka M, Tamaki N. 18F-FDG PET is superior to 67Ga SPECT in the staging of non-Hodgkin's lymphoma. Ann Nucl Med 2004 18 : 519 26.
-
(2004)
Ann Nucl Med
, vol.18
, pp. 519-26
-
-
Yamamoto, F.1
Tsukamoto, E.2
Nakada, K.3
Takei, T.4
Zhao, S.5
Asaka, M.6
Tamaki, N.7
-
15
-
-
0242266441
-
18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma
-
Zijlstra JM, Hoekstra OS, Raijmakers PG, Comans EF, van der Hoeven JJ, Teule GJ, Jonkhoff AR, Tinteren H, Lammertsma AA, Huijgens PC. 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2003 123 : 454 62.
-
(2003)
Br J Haematol
, vol.123
, pp. 454-62
-
-
Zijlstra, J.M.1
Hoekstra, O.S.2
Raijmakers, P.G.3
Comans, E.F.4
Van Der Hoeven, J.J.5
Teule, G.J.6
Jonkhoff, A.R.7
Tinteren, H.8
Lammertsma, A.A.9
Huijgens, P.C.10
-
16
-
-
0030930009
-
Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma
-
Hoh CK, Glaspy J, Rosen P, Dahlbom M, Lee SJ, Kunkel L, Hawkin RA, Maddahi J, Phelps ME. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997 38 : 343 8.
-
(1997)
J Nucl Med
, vol.38
, pp. 343-8
-
-
Hoh, C.K.1
Glaspy, J.2
Rosen, P.3
Dahlbom, M.4
Lee, S.J.5
Kunkel, L.6
Hawkin, R.A.7
Maddahi, J.8
Phelps, M.E.9
-
17
-
-
0030988191
-
Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging
-
Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, Kolokythas O, Herrmann F, Reske SN. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997 203 : 795 800.
-
(1997)
Radiology
, vol.203
, pp. 795-800
-
-
Moog, F.1
Bangerter, M.2
Diederichs, C.G.3
Guhlmann, A.4
Kotzerke, J.5
Merkle, E.6
Kolokythas, O.7
Herrmann, F.8
Reske, S.N.9
-
18
-
-
0031940343
-
Extranodal malignant lymphoma: Detection with FDG PET versus CT
-
Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E, Frickhofen N, Reske SN. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998 206 : 475 81.
-
(1998)
Radiology
, vol.206
, pp. 475-81
-
-
Moog, F.1
Bangerter, M.2
Diederichs, C.G.3
Guhlmann, A.4
Merkle, E.5
Frickhofen, N.6
Reske, S.N.7
-
19
-
-
0031869324
-
Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography
-
Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998 25 : 721 8.
-
(1998)
Eur J Nucl Med
, vol.25
, pp. 721-8
-
-
Stumpe, K.D.1
Urbinelli, M.2
Steinert, H.C.3
Glanzmann, C.4
Buck, A.5
Von Schulthess, G.K.6
-
20
-
-
0032587391
-
Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma
-
Jerusalem G, Warland V, Najjar F, Paulus P, Fassotte MF, Fillet G, Rigo P. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999 20 : 13 20.
-
(1999)
Nucl Med Commun
, vol.20
, pp. 13-20
-
-
Jerusalem, G.1
Warland, V.2
Najjar, F.3
Paulus, P.4
Fassotte, M.F.5
Fillet, G.6
Rigo, P.7
-
21
-
-
0034023608
-
The impact of FDG positron emission tomography imaging on the management of lymphomas
-
Shah N, Hoskin P, McMillan A, Gibson P, Lowe J, wong WL. The impact of FDG positron emission tomography imaging on the management of lymphomas. Br J Radiol 2000 73 : 482 7.
-
(2000)
Br J Radiol
, vol.73
, pp. 482-7
-
-
Shah, N.1
Hoskin, P.2
McMillan, A.3
Gibson, P.4
Lowe, J.5
Wong, W.L.6
-
22
-
-
0034909179
-
Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma
-
Schoder H, Meta J, Yap C, Ariannejad M, Rao J, Phelps ME, Valk PE, Sayre J, Czernin J. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001 42 : 1139 43.
-
(2001)
J Nucl Med
, vol.42
, pp. 1139-43
-
-
Schoder, H.1
Meta, J.2
Yap, C.3
Ariannejad, M.4
Rao, J.5
Phelps, M.E.6
Valk, P.E.7
Sayre, J.8
Czernin, J.9
-
23
-
-
0032848979
-
Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest
-
Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Bergmann L. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 1999 38 : 799 804.
-
(1999)
Acta Oncol
, vol.38
, pp. 799-804
-
-
Bangerter, M.1
Kotzerke, J.2
Griesshammer, M.3
Elsner, K.4
Reske, S.N.5
Bergmann, L.6
-
24
-
-
0036655324
-
Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma
-
Sasaki M, Kuwabara Y, Koga H, Nakagawa M, Chen T, Kaneko K, Hayashi K, Nakamura K, Masuda K. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med 2002 16 : 337 45.
-
(2002)
Ann Nucl Med
, vol.16
, pp. 337-45
-
-
Sasaki, M.1
Kuwabara, Y.2
Koga, H.3
Nakagawa, M.4
Chen, T.5
Kaneko, K.6
Hayashi, K.7
Nakamura, K.8
Masuda, K.9
-
25
-
-
0036211596
-
2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma
-
Delbeke D, Martin WH, Morgan DS, Kinney MC, Feurer I, Kovalsky E, Arrowsmith T, Greer JP. 2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma. Mol Imaging Biol 2002 4 : 105 14.
-
(2002)
Mol Imaging Biol
, vol.4
, pp. 105-14
-
-
Delbeke, D.1
Martin, W.H.2
Morgan, D.S.3
Kinney, M.C.4
Feurer, I.5
Kovalsky, E.6
Arrowsmith, T.7
Greer, J.P.8
-
26
-
-
0032876949
-
Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease
-
Wiedmann E, Baican B, Hertel A, Baum RP, Chow KU, Knupp B, Adams S, Hor G, Hoelzer D, Mitrou PS. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymphoma 1999 6 : 545 51.
-
(1999)
Leuk Lymphoma
, vol.6
, pp. 545-51
-
-
Wiedmann, E.1
Baican, B.2
Hertel, A.3
Baum, R.P.4
Chow, K.U.5
Knupp, B.6
Adams, S.7
Hor, G.8
Hoelzer, D.9
Mitrou, P.S.10
-
27
-
-
0033763664
-
2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution
-
Partridge S, Timothy A, O'Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000 11 : 1273 9.
-
(2000)
Ann Oncol
, vol.11
, pp. 1273-9
-
-
Partridge, S.1
Timothy, A.2
O'Doherty, M.J.3
Hain, S.F.4
Rankin, S.5
Mikhaeel, G.6
-
28
-
-
0035862970
-
Whole body positron emission tomography in the treatment of Hodgkin disease
-
Hueltenschmidt B, Sautter-Bihl ML, Lang O, Maul FD, Fischer J, Mergenthaler HG, Bihl H. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001 91 : 302 10.
-
(2001)
Cancer
, vol.91
, pp. 302-10
-
-
Hueltenschmidt, B.1
Sautter-Bihl, M.L.2
Lang, O.3
Maul, F.D.4
Fischer, J.5
Mergenthaler, H.G.6
Bihl, H.7
-
29
-
-
0035074636
-
Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease
-
Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001 86 : 266 73.
-
(2001)
Haematologica
, vol.86
, pp. 266-73
-
-
Jerusalem, G.1
Beguin, Y.2
Fassotte, M.F.3
Najjar, F.4
Paulus, P.5
Rigo, P.6
Fillet, G.7
-
30
-
-
0036405370
-
Positron emission tomography for the staging of Hodgkin's lymphoma - Increasing the body of evidence in favor of the method
-
Menzel C, Dobert N, Mitrou P, Mose S, Diehl M, Berner U, Grunwald F. Positron emission tomography for the staging of Hodgkin's lymphoma - increasing the body of evidence in favor of the method. Acta Oncol 2002 41 : 430 6.
-
(2002)
Acta Oncol
, vol.41
, pp. 430-6
-
-
Menzel, C.1
Dobert, N.2
Mitrou, P.3
Mose, S.4
Diehl, M.5
Berner, U.6
Grunwald, F.7
-
31
-
-
0036938607
-
Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease
-
Weihrauch MR, Re D, Bischoff S, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002 81 : 20 5.
-
(2002)
Ann Hematol
, vol.81
, pp. 20-5
-
-
Weihrauch, M.R.1
Re, D.2
Bischoff, S.3
-
32
-
-
0037810975
-
Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography-clinical use, interpretation methods, diagnostic improvements
-
Cohade C, Wahl RL. Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography-clinical use, interpretation methods, diagnostic improvements. Semin Nucl Med 2003 33 : 228 37.
-
(2003)
Semin Nucl Med
, vol.33
, pp. 228-37
-
-
Cohade, C.1
Wahl, R.L.2
-
33
-
-
10744230082
-
Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma
-
Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004 90 : 620 5.
-
(2004)
Br J Cancer
, vol.90
, pp. 620-5
-
-
Naumann, R.1
Beuthien-Baumann, B.2
Reiss, A.3
-
34
-
-
9444279658
-
Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease
-
Munker R, Glass J, Griffeth LK, Sattar T, Zamani R, Heldmann M, Shi R, Lilien DL. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol 2004 15 : 1699 704.
-
(2004)
Ann Oncol
, vol.15
, pp. 1699-704
-
-
Munker, R.1
Glass, J.2
Griffeth, L.K.3
Sattar, T.4
Zamani, R.5
Heldmann, M.6
Shi, R.7
Lilien, D.L.8
-
35
-
-
33645963756
-
Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma
-
Hutchings M, Loft A, Hansen M, Pedersen LM, Berthelsen AK, Keiding S, D'Amore F, Boesen AM, Roemer L, Specht L. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 2006 91 : 482 9.
-
(2006)
Haematologica
, vol.91
, pp. 482-9
-
-
Hutchings, M.1
Loft, A.2
Hansen, M.3
Pedersen, L.M.4
Berthelsen, A.K.5
Keiding, S.6
D'Amore, F.7
Boesen, A.M.8
Roemer, L.9
Specht, L.10
-
36
-
-
40849147717
-
Positron emission tomography in the staging of patients with Hodgkin's lymphoma. a prospective multicentric study by the Intergruppo Italiano Linfomi
-
Rigacci L, Vitolo U, Nassi L, et al. Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 2007 86 : 897 903.
-
(2007)
Ann Hematol
, vol.86
, pp. 897-903
-
-
Rigacci, L.1
Vitolo, U.2
Nassi, L.3
-
37
-
-
0031593417
-
Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease
-
Bangerter M, Moog F, Buchmann I, Kotzerke J, Griesshammer M, Hafner M, Elsner K, Frickhofen N, Reske SN, Bergmann L. Whole-body 2-[18F]-fluoro-2-deoxy- D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 1998 9 : 1117 22.
-
(1998)
Ann Oncol
, vol.9
, pp. 1117-22
-
-
Bangerter, M.1
Moog, F.2
Buchmann, I.3
Kotzerke, J.4
Griesshammer, M.5
Hafner, M.6
Elsner, K.7
Frickhofen, N.8
Reske, S.N.9
Bergmann, L.10
-
38
-
-
0035281784
-
2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. a bicenter trial
-
Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine-18)fluoro-2-deoxy- D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001 91 : 889 99.
-
(2001)
Cancer
, vol.91
, pp. 889-99
-
-
Buchmann, I.1
Reinhardt, M.2
Elsner, K.3
-
39
-
-
0032080192
-
Detection of lymphoma in bone marrow by whole-body positron emission tomography
-
Carr R, Barrington SF, Madan B, O'Doherty MJ, Saunders CA, van der WJ, Timothy AR. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998 91 : 3340 6.
-
(1998)
Blood
, vol.91
, pp. 3340-6
-
-
Carr, R.1
Barrington, S.F.2
Madan, B.3
O'Doherty, M.J.4
Saunders, C.A.5
Van Der, W.J.6
Timothy, A.R.7
-
40
-
-
23044475707
-
18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: A meta-analysis
-
Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005 46 : 958 63.
-
(2005)
J Nucl Med
, vol.46
, pp. 958-63
-
-
Pakos, E.E.1
Fotopoulos, A.D.2
Ioannidis, J.P.3
-
41
-
-
0032854418
-
Positron emission tomography in patients with primary CNS lymphomas
-
Roelcke U, Leenders KL. Positron emission tomography in patients with primary CNS lymphomas. J Neurooncol 1999 43 : 231 6.
-
(1999)
J Neurooncol
, vol.43
, pp. 231-6
-
-
Roelcke, U.1
Leenders, K.L.2
-
42
-
-
0037371152
-
18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma
-
Hoffmann M, Vogelsang H, Kletter K, Zettinig G, Chott A, Raderer M. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma. Gut 2003 52 : 347 51.
-
(2003)
Gut
, vol.52
, pp. 347-51
-
-
Hoffmann, M.1
Vogelsang, H.2
Kletter, K.3
Zettinig, G.4
Chott, A.5
Raderer, M.6
-
43
-
-
37149047466
-
The value of positron emission tomography/computed tomography (PET/CT) in the staging of diffuse large B-cell lymphoma
-
Fuertes S, Setoain X, Lopez-Guillermo A, Montserrat E, Fuster D, Paredes P, Lomena F, Pons F. The value of positron emission tomography/computed tomography (PET/CT) in the staging of diffuse large B-cell lymphoma. Med Clin (Barc) 2007 129 : 688 93.
-
(2007)
Med Clin (Barc)
, vol.129
, pp. 688-93
-
-
Fuertes, S.1
Setoain, X.2
Lopez-Guillermo, A.3
Montserrat, E.4
Fuster, D.5
Paredes, P.6
Lomena, F.7
Pons, F.8
-
44
-
-
0037974889
-
18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma
-
Hoffmann M, Kletter K, Becherer A, Jager U, Chott A, Raderer M. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003 64 : 336 40.
-
(2003)
Oncology
, vol.64
, pp. 336-40
-
-
Hoffmann, M.1
Kletter, K.2
Becherer, A.3
Jager, U.4
Chott, A.5
Raderer, M.6
-
45
-
-
2342529042
-
18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) does not visualize follicular lymphoma of the duodenum
-
Hoffmann M, Chott A, Puspok A, Jager U, Kletter K, Raderer M. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) does not visualize follicular lymphoma of the duodenum. Ann Hematol 2004 83 : 276 8.
-
(2004)
Ann Hematol
, vol.83
, pp. 276-8
-
-
Hoffmann, M.1
Chott, A.2
Puspok, A.3
Jager, U.4
Kletter, K.5
Raderer, M.6
-
46
-
-
33646181100
-
18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading
-
Wohrer S, Jaeger U, Kletter K, Becherer A, Hauswirth A, Turetschek K, Raderer M, Hoffmann M. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006 17 : 780 4.
-
(2006)
Ann Oncol
, vol.17
, pp. 780-4
-
-
Wohrer, S.1
Jaeger, U.2
Kletter, K.3
Becherer, A.4
Hauswirth, A.5
Turetschek, K.6
Raderer, M.7
Hoffmann, M.8
-
47
-
-
0034948354
-
Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL)
-
Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P, Fillet G. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001 12 : 825 30.
-
(2001)
Ann Oncol
, vol.12
, pp. 825-30
-
-
Jerusalem, G.1
Beguin, Y.2
Najjar, F.3
Hustinx, R.4
Fassotte, M.F.5
Rigo, P.6
Fillet, G.7
-
48
-
-
0038681075
-
Utility of FDG-PET scanning in lymphoma by WHO classification
-
Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003 101 : 3875 6.
-
(2003)
Blood
, vol.101
, pp. 3875-6
-
-
Elstrom, R.1
Guan, L.2
Baker, G.3
-
49
-
-
16244400833
-
FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: A report of 42 cases
-
Beal KP, Yeung HW, Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol 2005 16 : 473 80.
-
(2005)
Ann Oncol
, vol.16
, pp. 473-80
-
-
Beal, K.P.1
Yeung, H.W.2
Yahalom, J.3
-
50
-
-
0842263700
-
Positron emission tomography with [18F] 2-fluoro-D-2- deoxyglucose in primary cutaneous T-cell lymphomas
-
Valencak J, Becherer A, Der-Petrossian M, Trautinger F, Raderer M, Hoffmann M. Positron emission tomography with [18F] 2-fluoro-D-2- deoxyglucose in primary cutaneous T-cell lymphomas. Haematologica 2004 89 : 115 6.
-
(2004)
Haematologica
, vol.89
, pp. 115-6
-
-
Valencak, J.1
Becherer, A.2
Der-Petrossian, M.3
Trautinger, F.4
Raderer, M.5
Hoffmann, M.6
-
51
-
-
33745877593
-
Diagnostic role of 18F-FDG pet in gastric MALT lymphoma
-
Ambrosini V, Rubello D, Castellucci P, Nanni C, Farsad M, Zinzani P, Alavi A, Tehranipour N, Al Nahhas A, Fanti S. Diagnostic role of 18F-FDG pet in gastric MALT lymphoma. Nucl Med Rev Cent East Eur 2006 9 : 37 40.
-
(2006)
Nucl Med Rev Cent East Eur
, vol.9
, pp. 37-40
-
-
Ambrosini, V.1
Rubello, D.2
Castellucci, P.3
Nanni, C.4
Farsad, M.5
Zinzani, P.6
Alavi, A.7
Tehranipour, N.8
Al Nahhas, A.9
Fanti, S.10
-
52
-
-
0034790793
-
Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL)
-
Najjar F, Hustinx R, Jerusalem G, Fillet G, Rigo P. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL). Cancer Biother Radiopharm 2001 16 : 297 304.
-
(2001)
Cancer Biother Radiopharm
, vol.16
, pp. 297-304
-
-
Najjar, F.1
Hustinx, R.2
Jerusalem, G.3
Fillet, G.4
Rigo, P.5
-
53
-
-
23044469098
-
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma
-
Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi YE, Larson SM, Yeung HW. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005 23 : 4643 51.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4643-51
-
-
Schoder, H.1
Noy, A.2
Gonen, M.3
Weng, L.4
Green, D.5
Erdi, Y.E.6
Larson, S.M.7
Yeung, H.W.8
-
54
-
-
10244221207
-
Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma
-
Allen-Auerbach M, Quon A, Weber WA, Obrzut S, Crawford T, Silverman DH, Ratib O, Phelps ME, Czernin J. Comparison between 2-deoxy-2-[18F]fluoro-D- glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 2004 6 : 411 6.
-
(2004)
Mol Imaging Biol
, vol.6
, pp. 411-6
-
-
Allen-Auerbach, M.1
Quon, A.2
Weber, W.A.3
Obrzut, S.4
Crawford, T.5
Silverman, D.H.6
Ratib, O.7
Phelps, M.E.8
Czernin, J.9
-
55
-
-
0024422603
-
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting
-
Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989 7 : 1630 6.
-
(1989)
J Clin Oncol
, vol.7
, pp. 1630-6
-
-
Lister, T.A.1
Crowther, D.2
Sutcliffe, S.B.3
Glatstein, E.4
Canellos, G.P.5
Young, R.C.6
Rosenberg, S.A.7
Coltman, C.A.8
Tubiana, M.9
-
56
-
-
0026942042
-
Prognostic factors in Hodgkin's disease
-
Specht L. Prognostic factors in Hodgkin's disease. Dan Med Bull 1992 39 : 409 22.
-
(1992)
Dan Med Bull
, vol.39
, pp. 409-22
-
-
Specht, L.1
-
57
-
-
0027265218
-
Patterns of survival in patients with Hodgkin's disease: Long follow up in a single centre
-
Oza AM, Ganesan TS, Leahy M, Gregory W, Lim J, Dadiotis L, Barbounis V, Jones AE, Amess J, Stansfeld AG. Patterns of survival in patients with Hodgkin's disease: long follow up in a single centre. Ann Oncol 1993 4 : 385 92.
-
(1993)
Ann Oncol
, vol.4
, pp. 385-92
-
-
Oza, A.M.1
Ganesan, T.S.2
Leahy, M.3
Gregory, W.4
Lim, J.5
Dadiotis, L.6
Barbounis, V.7
Jones, A.E.8
Amess, J.9
Stansfeld, A.G.10
-
58
-
-
0038128305
-
Assessment of response to therapy using conventional imaging
-
Rankin SC. Assessment of response to therapy using conventional imaging. Eur J Nucl Med Mol Imaging 2003 30 (Suppl 1 S56 64.
-
(2003)
Eur J Nucl Med Mol Imaging
, vol.30
, Issue.1
-
-
Rankin, S.C.1
-
59
-
-
0022600848
-
Chemotherapy for diffuse large-cell lymphoma - Rapidly responding patients have more durable remissions
-
Armitage JO, Weisenburger DD, Hutchins M, Moravec DF, Dowling M, Sorensen S, Mailliard J, Okerbloom J, Johnson PS, Howe D. Chemotherapy for diffuse large-cell lymphoma - rapidly responding patients have more durable remissions. J Clin Oncol 1986 4 : 160 4.
-
(1986)
J Clin Oncol
, vol.4
, pp. 160-4
-
-
Armitage, J.O.1
Weisenburger, D.D.2
Hutchins, M.3
Moravec, D.F.4
Dowling, M.5
Sorensen, S.6
Mailliard, J.7
Okerbloom, J.8
Johnson, P.S.9
Howe, D.10
-
60
-
-
0002278336
-
Clinical Evaluation and Staging
-
In: Mauch, P., Armitage, J.O., Diehl, V., Hoppe, R., Weiss, L.M., eds. Philadelphia: Lippincott Williams and Wilkins
-
Gupta RK, Gospodarowicz MK, Lister TA. Clinical Evaluation and Staging. In : Mauch P, Armitage JO, Diehl V, Hoppe R, Weiss LM, eds. Hodgkin's Disease. Philadelphia : Lippincott Williams and Wilkins, 1999 : 223 40.
-
(1999)
Hodgkin's Disease.
, pp. 223-40
-
-
Gupta, R.K.1
Gospodarowicz, M.K.2
Lister, T.A.3
-
61
-
-
0023899907
-
Residual mass in lymphoma may not be residual disease
-
Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988 6 : 931 3.
-
(1988)
J Clin Oncol
, vol.6
, pp. 931-3
-
-
Canellos, G.P.1
-
62
-
-
0033624050
-
Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma
-
Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000 85 : 613 8.
-
(2000)
Haematologica
, vol.85
, pp. 613-8
-
-
Jerusalem, G.1
Beguin, Y.2
Fassotte, M.F.3
Najjar, F.4
Paulus, P.5
Rigo, P.6
Fillet, G.7
-
63
-
-
0034485716
-
18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT
-
Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leuk Lymphoma 2000 6 : 543 53.
-
(2000)
Leuk Lymphoma
, vol.6
, pp. 543-53
-
-
Mikhaeel, N.G.1
Timothy, A.R.2
O'Doherty, M.J.3
Hain, S.4
Maisey, M.N.5
-
64
-
-
0036739436
-
Early restaging positron emission tomography with (18)F- fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma
-
Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, Balzarini J, Wolf-Peeters C, Mortelmans L, Verhoef G. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002 13 : 1356 63.
-
(2002)
Ann Oncol
, vol.13
, pp. 1356-63
-
-
Spaepen, K.1
Stroobants, S.2
Dupont, P.3
Vandenberghe, P.4
Thomas, J.5
De Groot, T.6
Balzarini, J.7
Wolf-Peeters, C.8
Mortelmans, L.9
Verhoef, G.10
-
65
-
-
0027363708
-
Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy
-
Hoekstra OS, Ossenkoppele GJ, Golding R, van Lingen A, Visser GW, Teule GJ, Huijgens PC. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 1993 34 : 1706 10.
-
(1993)
J Nucl Med
, vol.34
, pp. 1706-10
-
-
Hoekstra, O.S.1
Ossenkoppele, G.J.2
Golding, R.3
Van Lingen, A.4
Visser, G.W.5
Teule, G.J.6
Huijgens, P.C.7
-
66
-
-
0036327331
-
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease
-
Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002 43 : 1018 27.
-
(2002)
J Nucl Med
, vol.43
, pp. 1018-27
-
-
Kostakoglu, L.1
Coleman, M.2
Leonard, J.P.3
Kuji, I.4
Zoe, H.5
Goldsmith, S.J.6
-
67
-
-
1642471698
-
Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma
-
Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, Kobayashi M, Ouchi Y. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004 31 : 22 8.
-
(2004)
Eur J Nucl Med Mol Imaging
, vol.31
, pp. 22-8
-
-
Torizuka, T.1
Nakamura, F.2
Kanno, T.3
Futatsubashi, M.4
Yoshikawa, E.5
Okada, H.6
Kobayashi, M.7
Ouchi, Y.8
-
68
-
-
24044553298
-
FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma
-
Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005 16 : 1514 23.
-
(2005)
Ann Oncol
, vol.16
, pp. 1514-23
-
-
Mikhaeel, N.G.1
Hutchings, M.2
Fields, P.A.3
O'Doherty, M.J.4
Timothy, A.R.5
-
69
-
-
23744498053
-
[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome
-
Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005 106 : 1376 81.
-
(2005)
Blood
, vol.106
, pp. 1376-81
-
-
Haioun, C.1
Itti, E.2
Rahmouni, A.3
-
70
-
-
25444437438
-
Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
-
Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005 16 : 1160 8.
-
(2005)
Ann Oncol
, vol.16
, pp. 1160-8
-
-
Hutchings, M.1
Mikhaeel, N.G.2
Fields, P.A.3
Nunan, T.4
Timothy, A.R.5
-
71
-
-
30144432586
-
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
-
Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006 107 : 52 9.
-
(2006)
Blood
, vol.107
, pp. 52-9
-
-
Hutchings, M.1
Loft, A.2
Hansen, M.3
-
72
-
-
33747873263
-
Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin's disease patients
-
Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 2006 17 : 1296 300.
-
(2006)
Ann Oncol
, vol.17
, pp. 1296-300
-
-
Zinzani, P.L.1
Tani, M.2
Fanti, S.3
-
73
-
-
33645998113
-
The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease
-
Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006 91 : 475 81.
-
(2006)
Haematologica
, vol.91
, pp. 475-81
-
-
Gallamini, A.1
Rigacci, L.2
Merli, F.3
-
74
-
-
34548486030
-
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study
-
Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007 25 : 3746 52.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3746-52
-
-
Gallamini, A.1
Hutchings, M.2
Rigacci, L.3
-
75
-
-
29244432478
-
Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?
-
Girinsky T, Pichenot C, Beaudre A, Ghalibafian M, Lefkopoulos D. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 2006 64 : 218 26.
-
(2006)
Int J Radiat Oncol Biol Phys
, vol.64
, pp. 218-26
-
-
Girinsky, T.1
Pichenot, C.2
Beaudre, A.3
Ghalibafian, M.4
Lefkopoulos, D.5
-
76
-
-
33746346422
-
Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines
-
Girinsky T, van der Maazen R., Specht L, Aleman B, Poortmans P, Lievens Y, Meijnders P, Ghalibafian M, Meerwaldt J, Noordijk E. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006 79 : 270 7.
-
(2006)
Radiother Oncol
, vol.79
, pp. 270-7
-
-
Girinsky, T.1
Van Der Maazen, R.2
Specht, L.3
Aleman, B.4
Poortmans, P.5
Lievens, Y.6
Meijnders, P.7
Ghalibafian, M.8
Meerwaldt, J.9
Noordijk, E.10
-
77
-
-
0031934031
-
Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: A meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group
-
Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998 16 : 830 43.
-
(1998)
J Clin Oncol
, vol.16
, pp. 830-43
-
-
Specht, L.1
Gray, R.G.2
Clarke, M.J.3
Peto, R.4
-
78
-
-
21044443290
-
Transformation in the use of radiation therapy of Hodgkin lymphoma: New concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT)
-
Yahalom J. Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur J Haematol Suppl 2005 66 : 90 7.
-
(2005)
Eur J Haematol Suppl
, vol.66
, pp. 90-7
-
-
Yahalom, J.1
-
79
-
-
36349025232
-
Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting?
-
Girinsky T, Ghalibafian M, Bonniaud G, Bayla A, Magne N, Ferreira I, Lumbroso J. Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? Radiother Oncol 2007 85 : 178 86.
-
(2007)
Radiother Oncol
, vol.85
, pp. 178-86
-
-
Girinsky, T.1
Ghalibafian, M.2
Bonniaud, G.3
Bayla, A.4
Magne, N.5
Ferreira, I.6
Lumbroso, J.7
-
80
-
-
10044273157
-
Is there any future in radiotherapy planning without the use of PET: Unraveling the myth
-
Gregoire V. Is there any future in radiotherapy planning without the use of PET: unraveling the myth. Radiother Oncol 2004 73 : 261 3.
-
(2004)
Radiother Oncol
, vol.73
, pp. 261-3
-
-
Gregoire, V.1
-
82
-
-
34250698039
-
2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas
-
Specht L. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. Semin Radiat Oncol 2007 17 : 190 7.
-
(2007)
Semin Radiat Oncol
, vol.17
, pp. 190-7
-
-
Specht, L.1
-
83
-
-
33745535722
-
The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning
-
van Baardwijk A, Baumert BG, Bosmans G, van Kroonenburgh M, Stroobants S, Gregoire V, Lambin P, De Ruysscher D. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev 2006 32 : 245 60.
-
(2006)
Cancer Treat Rev
, vol.32
, pp. 245-60
-
-
Van Baardwijk, A.1
Baumert, B.G.2
Bosmans, G.3
Van Kroonenburgh, M.4
Stroobants, S.5
Gregoire, V.6
Lambin, P.7
De Ruysscher, D.8
-
84
-
-
0037224978
-
Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy
-
Dizendorf EV, Baumert BG, von Schulthess GK, Lutolf UM, Steinert HC. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 2003 44 : 24 9.
-
(2003)
J Nucl Med
, vol.44
, pp. 24-9
-
-
Dizendorf, E.V.1
Baumert, B.G.2
Von Schulthess, G.K.3
Lutolf, U.M.4
Steinert, H.C.5
-
85
-
-
10044246142
-
Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma
-
Lee YK, Cook G, Flower MA, Rowbottom C, Shahidi M, Sharma B, Webb S. Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma. Radiother Oncol 2004 73 : 277 83.
-
(2004)
Radiother Oncol
, vol.73
, pp. 277-83
-
-
Lee, Y.K.1
Cook, G.2
Flower, M.A.3
Rowbottom, C.4
Shahidi, M.5
Sharma, B.6
Webb, S.7
-
86
-
-
33846965941
-
Clinical impact of FDG-PET/CT in the planning of radiotherapy for early stage Hodgkin lymphoma
-
Hutchings M, Berthelsen AK, Loft A, Hansen M, Specht L. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early stage Hodgkin lymphoma. Eur J Haematol 2007 78 : 206 12.
-
(2007)
Eur J Haematol
, vol.78
, pp. 206-12
-
-
Hutchings, M.1
Berthelsen, A.K.2
Loft, A.3
Hansen, M.4
Specht, L.5
-
87
-
-
1642335524
-
Positron emission tomography in pediatric radiation oncology: Integration in the treatment-planning process
-
Krasin MJ, Hudson MM, Kaste SC. Positron emission tomography in pediatric radiation oncology: integration in the treatment-planning process. Pediatr Radiol 2004 34 : 214 21.
-
(2004)
Pediatr Radiol
, vol.34
, pp. 214-21
-
-
Krasin, M.J.1
Hudson, M.M.2
Kaste, S.C.3
-
88
-
-
0042449063
-
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group
-
Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999 17 : 1244.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1244
-
-
Cheson, B.D.1
Horning, S.J.2
Coiffier, B.3
-
90
-
-
34247855900
-
PET and PET/CT for response evaluation in lymphoma: Current practice and developments
-
Brepoels L, Stroobants S, Verhoef G. PET and PET/CT for response evaluation in lymphoma: current practice and developments. Leuk Lymphoma 2007 48 : 270 82.
-
(2007)
Leuk Lymphoma
, vol.48
, pp. 270-82
-
-
Brepoels, L.1
Stroobants, S.2
Verhoef, G.3
-
91
-
-
0031742182
-
Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma
-
Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998 19 : 1055 63.
-
(1998)
Nucl Med Commun
, vol.19
, pp. 1055-63
-
-
Cremerius, U.1
Fabry, U.2
Neuerburg, J.3
Zimny, M.4
Osieka, R.5
Buell, U.6
-
92
-
-
0030978419
-
Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma
-
de Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997 8 (Suppl. 1 57 60.
-
(1997)
Ann Oncol
, vol.8
, Issue.1
, pp. 57-60
-
-
De Wit, M.1
Bumann, D.2
Beyer, W.3
Herbst, K.4
Clausen, M.5
Hossfeld, D.K.6
-
93
-
-
0034746308
-
18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma
-
de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001 12 : 29 37.
-
(2001)
Ann Oncol
, vol.12
, pp. 29-37
-
-
De Wit, M.1
Bohuslavizki, K.H.2
Buchert, R.3
Bumann, D.4
Clausen, M.5
Hossfeld, D.K.6
-
94
-
-
0035514722
-
Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma
-
Dittmann H, Sokler M, Kollmannsberger C, Dohmen BM, Baumann C, Kopp A, Bares R, Claussen CD, Kanz L, Bokemeyer C. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep 2001 8 : 1393 9.
-
(2001)
Oncol Rep
, vol.8
, pp. 1393-9
-
-
Dittmann, H.1
Sokler, M.2
Kollmannsberger, C.3
Dohmen, B.M.4
Baumann, C.5
Kopp, A.6
Bares, R.7
Claussen, C.D.8
Kanz, L.9
Bokemeyer, C.10
-
95
-
-
12144286610
-
FDG-PET/CT in re-staging of patients with lymphoma
-
Freudenberg LS, Antoch G, Schutt P, Beyer T, Jentzen W, Muller SP, Gorges R, Nowrousian MR, Bockisch A, Debatin JF. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004 31 : 325 9.
-
(2004)
Eur J Nucl Med Mol Imaging
, vol.31
, pp. 325-9
-
-
Freudenberg, L.S.1
Antoch, G.2
Schutt, P.3
Beyer, T.4
Jentzen, W.5
Muller, S.P.6
Gorges, R.7
Nowrousian, M.R.8
Bockisch, A.9
Debatin, J.F.10
-
96
-
-
0141557973
-
Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation
-
Guay C, Lepine M, Verreault J, Benard F. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 2003 44 : 1225 31.
-
(2003)
J Nucl Med
, vol.44
, pp. 1225-31
-
-
Guay, C.1
Lepine, M.2
Verreault, J.3
Benard, F.4
-
97
-
-
0033566341
-
Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
-
Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999 94 : 429 33.
-
(1999)
Blood
, vol.94
, pp. 429-33
-
-
Jerusalem, G.1
Beguin, Y.2
Fassotte, M.F.3
Najjar, F.4
Paulus, P.5
Rigo, P.6
Fillet, G.7
-
98
-
-
13244291766
-
FDG PET in the evaluation of treatment for lymphoma: Clinical usefulness and pitfalls
-
Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics 2005 25 : 191 207.
-
(2005)
Radiographics
, vol.25
, pp. 191-207
-
-
Kazama, T.1
Faria, S.C.2
Varavithya, V.3
Phongkitkarun, S.4
Ito, H.5
MacApinlac, H.A.6
-
99
-
-
0035104060
-
Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease
-
Lang O, Bihl H, Hultenschmidt B, Sautter-Bihl ML. Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease. Strahlenther Onkol 2001 177 : 138 44.
-
(2001)
Strahlenther Onkol
, vol.177
, pp. 138-44
-
-
Lang, O.1
Bihl, H.2
Hultenschmidt, B.3
Sautter-Bihl, M.L.4
-
100
-
-
0041381273
-
FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy
-
Lavely WC, Delbeke D, Greer JP, Morgan DS, Byrne DW, Price RR, Hallahan DE. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys 2003 57 : 307 15.
-
(2003)
Int J Radiat Oncol Biol Phys
, vol.57
, pp. 307-15
-
-
Lavely, W.C.1
Delbeke, D.2
Greer, J.P.3
Morgan, D.S.4
Byrne, D.W.5
Price, R.R.6
Hallahan, D.E.7
-
101
-
-
0033621989
-
Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?
-
Maisey NR, Hill ME, Webb A, Cunningham D, Flux GD, Padhani A, Ott RJ, Norman A, Bishop L. Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer 2000 36 : 200 6.
-
(2000)
Eur J Cancer
, vol.36
, pp. 200-6
-
-
Maisey, N.R.1
Hill, M.E.2
Webb, A.3
Cunningham, D.4
Flux, G.D.5
Padhani, A.6
Ott, R.J.7
Norman, A.8
Bishop, L.9
-
102
-
-
0033996693
-
18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas
-
Mikhaeel NG, Timothy AR, Hain SF, O'Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 2000 11 (Suppl. 1 147 50.
-
(2000)
Ann Oncol
, vol.11
, Issue.1
, pp. 147-50
-
-
Mikhaeel, N.G.1
Timothy, A.R.2
Hain, S.F.3
O'Doherty, M.J.4
-
103
-
-
0035676671
-
Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma
-
Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, Franke WG, Ehninger G. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001 115 : 793 800.
-
(2001)
Br J Haematol
, vol.115
, pp. 793-800
-
-
Naumann, R.1
Vaic, A.2
Beuthien-Baumann, B.3
Bredow, J.4
Kropp, J.5
Kittner, T.6
Franke, W.G.7
Ehninger, G.8
-
104
-
-
3242889932
-
Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses
-
Panizo C, Perez-Salazar M, Bendandi M, Rodriguez-Calvillo M, Boan JF, Garcia-Velloso MJ, Richter J, Rocha E. Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses. Leuk Lymphoma 2004 45 : 1829 33.
-
(2004)
Leuk Lymphoma
, vol.45
, pp. 1829-33
-
-
Panizo, C.1
Perez-Salazar, M.2
Bendandi, M.3
Rodriguez-Calvillo, M.4
Boan, J.F.5
Garcia-Velloso, M.J.6
Richter, J.7
Rocha, E.8
-
105
-
-
33645011656
-
Quantitative CT analysis for assessing response in lymphoma (Cheson's criteria)
-
Spec No A:
-
Rahmouni A, Luciani A, Itti E. Quantitative CT analysis for assessing response in lymphoma (Cheson's criteria). Cancer Imaging 2005 5 Spec No A : S102 6.
-
(2005)
Cancer Imaging
, vol.5
-
-
Rahmouni, A.1
Luciani, A.2
Itti, E.3
-
106
-
-
24044475903
-
Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: When do we really need FDG-PET?
-
Reinhardt MJ, Herkel C, Altehoefer C, Finke J, Moser E. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET? Ann Oncol 2005 16 : 1524 9.
-
(2005)
Ann Oncol
, vol.16
, pp. 1524-9
-
-
Reinhardt, M.J.1
Herkel, C.2
Altehoefer, C.3
Finke, J.4
Moser, E.5
-
107
-
-
0038409977
-
PET and restaging of malignant lymphoma including residual masses and relapse
-
Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 2003 30 (Suppl. 1 S89 96.
-
(2003)
Eur J Nucl Med Mol Imaging
, vol.30
, Issue.1
-
-
Reske, S.N.1
-
108
-
-
27744560443
-
18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: Long-term results
-
Rigacci L, Castagnoli A, Dini C, et al. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results. Oncol Rep 2005 14 : 1209 14.
-
(2005)
Oncol Rep
, vol.14
, pp. 1209-14
-
-
Rigacci, L.1
Castagnoli, A.2
Dini, C.3
-
109
-
-
0035725231
-
Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
-
Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, Wolf-Peeters C, Mortelmans L, Verhoef G. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001 115 : 272 8.
-
(2001)
Br J Haematol
, vol.115
, pp. 272-8
-
-
Spaepen, K.1
Stroobants, S.2
Dupont, P.3
Thomas, J.4
Vandenberghe, P.5
Balzarini, J.6
Wolf-Peeters, C.7
Mortelmans, L.8
Verhoef, G.9
-
110
-
-
0035863387
-
Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
-
Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001 19 : 414 9.
-
(2001)
J Clin Oncol
, vol.19
, pp. 414-9
-
-
Spaepen, K.1
Stroobants, S.2
Dupont, P.3
-
111
-
-
19244367762
-
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
-
Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001 98 : 2930 4.
-
(2001)
Blood
, vol.98
, pp. 2930-4
-
-
Weihrauch, M.R.1
Re, D.2
Scheidhauer, K.3
-
112
-
-
33645999354
-
18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: A systematic review
-
Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006 91 : 522 9.
-
(2006)
Haematologica
, vol.91
, pp. 522-9
-
-
Zijlstra, J.M.1
Lindauer-Van Der Werf, G.2
Hoekstra, O.S.3
Hooft, L.4
Riphagen, I.I.5
Huijgens, P.C.6
-
113
-
-
23044497490
-
Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography
-
Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005 23 : 4652 61.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4652-61
-
-
Juweid, M.E.1
Wiseman, G.A.2
Vose, J.M.3
-
114
-
-
33947496614
-
Revised Response Criteria for Malignant Lymphoma
-
Cheson BD, Pfistner B, Juweid ME, et al. Revised Response Criteria for Malignant Lymphoma. J Clin Oncol 2007 25 : 579 86.
-
(2007)
J Clin Oncol
, vol.25
, pp. 579-86
-
-
Cheson, B.D.1
Pfistner, B.2
Juweid, M.E.3
-
115
-
-
33947512956
-
Use of positron emission tomography (PET) for response assessment of lymphoma: Consensus of the Imaging Subcommittee of the International Harmonization Project in Lymphoma
-
Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography (PET) for response assessment of lymphoma: consensus of the Imaging Subcommittee of the International Harmonization Project in Lymphoma. J Clin Oncol 2007 25 : 571 8.
-
(2007)
J Clin Oncol
, vol.25
, pp. 571-8
-
-
Juweid, M.E.1
Stroobants, S.2
Hoekstra, O.S.3
-
116
-
-
34547978802
-
Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by integrated international workshop criteria
-
Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J, Uyttebroeck A, Mortelmans L, Wolf-Peeters C, Verhoef G. Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria. Leuk Lymphoma 2007 48 : 1522 30.
-
(2007)
Leuk Lymphoma
, vol.48
, pp. 1522-30
-
-
Brepoels, L.1
Stroobants, S.2
De Wever, W.3
Spaepen, K.4
Vandenberghe, P.5
Thomas, J.6
Uyttebroeck, A.7
Mortelmans, L.8
Wolf-Peeters, C.9
Verhoef, G.10
-
117
-
-
34547972405
-
Hodgkin lymphoma: Response assessment by revised International Workshop Criteria
-
Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J, Uyttebroeck A, Mortelmans L, Wolf-Peeters C, Verhoef G. Hodgkin lymphoma: response assessment by revised International Workshop Criteria. Leuk Lymphoma 2007 48 : 1539 47.
-
(2007)
Leuk Lymphoma
, vol.48
, pp. 1539-47
-
-
Brepoels, L.1
Stroobants, S.2
De Wever, W.3
Spaepen, K.4
Vandenberghe, P.5
Thomas, J.6
Uyttebroeck, A.7
Mortelmans, L.8
Wolf-Peeters, C.9
Verhoef, G.10
-
118
-
-
34548575042
-
Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: A randomized study caveat
-
Yahalom J. Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: a randomized study caveat. Leuk Lymphoma 2007 48 : 1667 9.
-
(2007)
Leuk Lymphoma
, vol.48
, pp. 1667-9
-
-
Yahalom, J.1
-
119
-
-
34548546788
-
Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans
-
Picardi M, De Renzo A, Pane F, Nicolai E, Pacelli R, Salvatore M, Rotoli B. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 2007 48 : 1721 7.
-
(2007)
Leuk Lymphoma
, vol.48
, pp. 1721-7
-
-
Picardi, M.1
De Renzo, A.2
Pane, F.3
Nicolai, E.4
Pacelli, R.5
Salvatore, M.6
Rotoli, B.7
-
120
-
-
0037250291
-
Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease
-
Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, Fillet G. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003 14 : 123 30.
-
(2003)
Ann Oncol
, vol.14
, pp. 123-30
-
-
Jerusalem, G.1
Beguin, Y.2
Fassotte, M.F.3
Belhocine, T.4
Hustinx, R.5
Rigo, P.6
Fillet, G.7
-
121
-
-
34347253223
-
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma
-
Zinzani PL, Tani M, Trisolini R, et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica 2007 92 : 771 7.
-
(2007)
Haematologica
, vol.92
, pp. 771-7
-
-
Zinzani, P.L.1
Tani, M.2
Trisolini, R.3
-
122
-
-
0033890745
-
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - A groupe d'Etude des lymphomes de l'Adulte study
-
Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000 18 : 3025 30.
-
(2000)
J Clin Oncol
, vol.18
, pp. 3025-30
-
-
Haioun, C.1
Lepage, E.2
Gisselbrecht, C.3
-
123
-
-
0031962299
-
Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: Value of augmented preparative regimens - A Southwest Oncology Group trial
-
Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens - a Southwest Oncology Group trial. J Clin Oncol 1998 16 : 48 55.
-
(1998)
J Clin Oncol
, vol.16
, pp. 48-55
-
-
Stiff, P.J.1
Dahlberg, S.2
Forman, S.J.3
McCall, A.R.4
Horning, S.J.5
Nademanee, A.P.6
Blume, K.G.7
Leblanc, M.8
Fisher, R.I.9
-
124
-
-
0036169215
-
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation
-
Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HT, Karanikas G, Potzi C, Raderer M, Dudczak R, Kletter K. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002 16 : 260 7.
-
(2002)
Leukemia
, vol.16
, pp. 260-7
-
-
Becherer, A.1
Mitterbauer, M.2
Jaeger, U.3
Kalhs, P.4
Greinix, H.T.5
Karanikas, G.6
Potzi, C.7
Raderer, M.8
Dudczak, R.9
Kletter, K.10
-
125
-
-
0036050297
-
Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma
-
Cremerius U, Fabry U, Wildberger JE, Zimny M, Reinartz P, Nowak B, Schaefer W, Buell U, Osieka R. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002 30 : 103 11.
-
(2002)
Bone Marrow Transplant
, vol.30
, pp. 103-11
-
-
Cremerius, U.1
Fabry, U.2
Wildberger, J.E.3
Zimny, M.4
Reinartz, P.5
Nowak, B.6
Schaefer, W.7
Buell, U.8
Osieka, R.9
-
126
-
-
0037630376
-
Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation
-
Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003 102 : 53 9.
-
(2003)
Blood
, vol.102
, pp. 53-9
-
-
Spaepen, K.1
Stroobants, S.2
Dupont, P.3
-
127
-
-
0042231122
-
Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation
-
Filmont JE, Czernin J, Yap C, Silverman DH, Quon A, Phelps ME, Emmanouilides C. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 2003 124 : 608 13.
-
(2003)
Chest
, vol.124
, pp. 608-13
-
-
Filmont, J.E.1
Czernin, J.2
Yap, C.3
Silverman, D.H.4
Quon, A.5
Phelps, M.E.6
Emmanouilides, C.7
-
128
-
-
0036202025
-
Initial results in the assessment of multiple myeloma using 18F-FDG PET
-
Schirrmeister H, Bommer M, Buck AK, Muller S, Messer P, Bunjes D, Dohner H, Bergmann L, Reske SN. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002 29 : 361 6.
-
(2002)
Eur J Nucl Med Mol Imaging
, vol.29
, pp. 361-6
-
-
Schirrmeister, H.1
Bommer, M.2
Buck, A.K.3
Muller, S.4
Messer, P.5
Bunjes, D.6
Dohner, H.7
Bergmann, L.8
Reske, S.N.9
-
129
-
-
0036948617
-
Diagnostic utility of FDG PET in multiple myeloma
-
Jadvar H, Conti PS. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol 2002 31 : 690 4.
-
(2002)
Skeletal Radiol
, vol.31
, pp. 690-4
-
-
Jadvar, H.1
Conti, P.S.2
-
130
-
-
0242413757
-
Positron emission tomography (PET) for staging of solitary plasmacytoma
-
Schirrmeister H, Buck AK, Bergmann L, Reske SN, Bommer M. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm 2003 18 : 841 5.
-
(2003)
Cancer Biother Radiopharm
, vol.18
, pp. 841-5
-
-
Schirrmeister, H.1
Buck, A.K.2
Bergmann, L.3
Reske, S.N.4
Bommer, M.5
-
131
-
-
18244369257
-
Value of FDG PET in the assessment of patients with multiple myeloma
-
Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol 2005 184 : 1199 204.
-
(2005)
AJR Am J Roentgenol
, vol.184
, pp. 1199-204
-
-
Bredella, M.A.1
Steinbach, L.2
Caputo, G.3
Segall, G.4
Hawkins, R.5
-
132
-
-
33746933496
-
Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma
-
Breyer RJ III., Mulligan ME, Smith SE, Line BR, Badros AZ. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol 2006 35 : 632 40.
-
(2006)
Skeletal Radiol
, vol.35
, pp. 632-40
-
-
Breyer Iii., R.J.1
Mulligan, M.E.2
Smith, S.E.3
Line, B.R.4
Badros, A.Z.5
-
133
-
-
33646402351
-
Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: Preliminary results
-
Nanni C, Zamagni E, Farsad M, Castellucci P, Tosi P, Cangini D, Salizzoni E, Canini R, Cavo M, Fanti S. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging 2006 33 : 525 31.
-
(2006)
Eur J Nucl Med Mol Imaging
, vol.33
, pp. 525-31
-
-
Nanni, C.1
Zamagni, E.2
Farsad, M.3
Castellucci, P.4
Tosi, P.5
Cangini, D.6
Salizzoni, E.7
Canini, R.8
Cavo, M.9
Fanti, S.10
-
134
-
-
33846916461
-
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma
-
Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007 92 : 50 5.
-
(2007)
Haematologica
, vol.92
, pp. 50-5
-
-
Zamagni, E.1
Nanni, C.2
Patriarca, F.3
-
135
-
-
33746515610
-
The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging system
-
Durie BG. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer 2006 42 : 1539 43.
-
(2006)
Eur J Cancer
, vol.42
, pp. 1539-43
-
-
Durie, B.G.1
-
136
-
-
33947268684
-
Guidelines for the use of imaging in the management of myeloma
-
D'Sa S, Abildgaard N, Tighe J, Shaw P, Hall-Craggs M. Guidelines for the use of imaging in the management of myeloma. Br J Haematol 2007 137 : 49 63.
-
(2007)
Br J Haematol
, vol.137
, pp. 49-63
-
-
D'Sa, S.1
Abildgaard, N.2
Tighe, J.3
Shaw, P.4
Hall-Craggs, M.5
-
138
-
-
0035130893
-
Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: A useful tool for the identification and follow-up of myeloma bone disease
-
Balleari E, Villa G, Garre S, et al. Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease. Haematologica 2001 86 : 78 84.
-
(2001)
Haematologica
, vol.86
, pp. 78-84
-
-
Balleari, E.1
Villa, G.2
Garre, S.3
-
139
-
-
28444462083
-
Comparison of Tc-99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma
-
Hung GU, Tsai CC, Tsai SC, Lin WY. Comparison of Tc-99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma. Anticancer Res 2005 25 : 4737 41.
-
(2005)
Anticancer Res
, vol.25
, pp. 4737-41
-
-
Hung, G.U.1
Tsai, C.C.2
Tsai, S.C.3
Lin, W.Y.4
-
140
-
-
24944582938
-
BaselinTc99-MIBI scanning predicts survival in multiple myeloma and helps to differentiate this disease from monoclonal gammopathy of unknown significance
-
Martin MG, Romero Colas MS, Dourdil Sahun MV, Olave P, Alba PR, Banzo JB. BaselinTc99-MIBI scanning predicts survival in multiple myeloma and helps to differentiate this disease from monoclonal gammopathy of unknown significance. Haematologica 2005 90 : 1141 3.
-
(2005)
Haematologica
, vol.90
, pp. 1141-3
-
-
Martin, M.G.1
Romero Colas, M.S.2
Dourdil Sahun, M.V.3
Olave, P.4
Alba, P.R.5
Banzo, J.B.6
-
141
-
-
0742269486
-
A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma
-
Mileshkin L, Blum R, Seymour JF, Patrikeos A, Hicks RJ, Prince HM. A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma. Eur J Haematol 2004 72 : 32 7.
-
(2004)
Eur J Haematol
, vol.72
, pp. 32-7
-
-
Mileshkin, L.1
Blum, R.2
Seymour, J.F.3
Patrikeos, A.4
Hicks, R.J.5
Prince, H.M.6
-
142
-
-
34748853726
-
FDG PET findings of chronic myeloid leukemia in the chronic phase before and after treatment
-
Nakajo M, Jinnouchi S, Inoue H, Otsuka M, Matsumoto T, Kukita T, Tanabe H, Tateno R, Nakajo M. FDG PET findings of chronic myeloid leukemia in the chronic phase before and after treatment. Clin Nucl Med 2007 32 : 775 8.
-
(2007)
Clin Nucl Med
, vol.32
, pp. 775-8
-
-
Nakajo, M.1
Jinnouchi, S.2
Inoue, H.3
Otsuka, M.4
Matsumoto, T.5
Kukita, T.6
Tanabe, H.7
Tateno, R.8
Nakajo, M.9
-
143
-
-
13644264936
-
Diffuse bone marrow accumulation of FDG in a patient with chronic myeloid leukemia mimics hematopoietic cytokine-mediated FDG uptake on positron emission tomography
-
Takalkar A, Yu JQ, Kumar R, Xiu Y, Alavi A, Zhuang H. Diffuse bone marrow accumulation of FDG in a patient with chronic myeloid leukemia mimics hematopoietic cytokine-mediated FDG uptake on positron emission tomography. Clin Nucl Med 2004 29 : 637 9.
-
(2004)
Clin Nucl Med
, vol.29
, pp. 637-9
-
-
Takalkar, A.1
Yu, J.Q.2
Kumar, R.3
Xiu, Y.4
Alavi, A.5
Zhuang, H.6
|